Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

Abstract:

:The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes mellitus (T2DM) as well as their co-existence necessitate that anti-diabetic pharmacotherapy will modulate the cardiovascular risk inherent to T2DM while complying with the accompanying restrictions imposed by CHF. The thiazolidinedione (TZD) family of peroxisome proliferator-activated receptor γ (PPARγ) agonists initially provided a promising therapeutic option in T2DM owing to anti-diabetic efficacy combined with pleiotropic beneficial cardiovascular effects. However, the utility of TZDs in T2DM has declined in the past decade, largely due to concomitant adverse effects of fluid retention and edema formation attributed to salt-retaining effects of PPARγ activation on the nephron. Presumably, the latter effects are potentially deleterious in the context of pre-existing fluid retention in CHF. However, despite a considerable body of evidence on mechanisms responsible for TZD-induced fluid retention suggesting that this class of drugs is rightfully prohibited from use in CHF patients, there is a paucity of experimental and clinical studies that investigate the effects of TZDs on salt and water homeostasis in the CHF setting. In an attempt to elucidate whether TZDs actually exacerbate the pre-existing fluid retention in CHF, our review summarizes the pathophysiology of fluid retention in CHF. Moreover, we thoroughly review the available data on TZD-induced fluid retention and proposed mechanisms in animals and patients. Finally, we will present recent studies challenging the common notion that TZDs worsen renal salt and water retention in CHF.

journal_name

Pharmacol Ther

authors

Goltsman I,Khoury EE,Winaver J,Abassi Z

doi

10.1016/j.pharmthera.2016.09.007

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

75-97

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(16)30163-2

journal_volume

168

pub_type

杂志文章,评审
  • The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review.

    abstract::The 90-kDa molecular chaperone family (which comprises, among other proteins, the 90-kDa heat-shock protein, hsp90 and the 94-kDa glucose-regulated protein, grp94, major molecular chaperones of the cytosol and of the endoplasmic reticulum, respectively) has become an increasingly active subject of research in the past...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(98)00013-8

    authors: Csermely P,Schnaider T,Soti C,Prohászka Z,Nardai G

    更新日期:1998-08-01 00:00:00

  • Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.

    abstract::Injury to peripheral or spinal nerves following either trauma or disease has several consequences including the development of neuropathic pain. This syndrome is often refractory against conventional analgesics; and thus, novel medicaments are desired for its treatment. Recent studies have emphasized that dysfunction ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.pharmthera.2009.03.018

    authors: Dohi T,Morita K,Kitayama T,Motoyama N,Morioka N

    更新日期:2009-07-01 00:00:00

  • RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target.

    abstract::RANKL is a key molecule that bridges the bone and immune systems. RANKL stimulation activates a signaling pathway downstream of RANK, thereby determining the extent of bone resorption by inducing osteoclast maturation. The signaling pathway also regulates the development of different lymphoid organs, including the thy...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107682

    authors: Honma M,Ikebuchi Y,Suzuki H

    更新日期:2021-02-01 00:00:00

  • Extracellular vesicles and their nucleic acids for biomarker discovery.

    abstract::Extracellular vesicles (EVs) are a heterogenous population of vesicles originate from cells. EVs are found in different biofluids and carry different macromolecules, including proteins, lipids, and nucleic acids, providing a snap shot of the parental cells at the time of release. EVs have the ability to transfer molec...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.002

    authors: Momen-Heravi F,Getting SJ,Moschos SA

    更新日期:2018-12-01 00:00:00

  • Perinatal changes in pulmonary vascular endothelial function.

    abstract::The pulmonary endothelium plays a crucial role in lung development and function during the perinatal period. Its 2 most important functions at this time are to help reduce pulmonary vascular resistance (PVR) in order to permit the entire cardiac output to pass through the lungs for the first time and to facilitate the...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.06.016

    authors: Wojciak-Stothard B,Haworth SG

    更新日期:2006-01-01 00:00:00

  • Role of inflammatory chemokines in hypertension.

    abstract::Hypertension is associated with immune cells activation and their migration into the kidney, vasculature, heart and brain. These inflammatory mechanisms are critical for blood pressure regulation and mediate target organ damage, creating unique novel targets for pharmacological modulation. In response to angiotensin I...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107799

    authors: Mikolajczyk TP,Szczepaniak P,Vidler F,Maffia P,Graham GJ,Guzik TJ

    更新日期:2020-12-24 00:00:00

  • Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans.

    abstract::Evidence has accumulated indicating that the interaction between NO and the autonomic nervous system plays an important role in cardiovascular regulation, not only in experimental animals, but also in humans. NO interacts with the autonomic nervous system both at the central level and peripherally. In this review, we ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.11.009

    authors: Sartori C,Lepori M,Scherrer U

    更新日期:2005-05-01 00:00:00

  • Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.

    abstract::Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00015-9

    authors: Aihara T,Nakamura E,Amagase K,Tomita K,Fujishita T,Furutani K,Okabe S

    更新日期:2003-04-01 00:00:00

  • New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells.

    abstract::For decades, intensive studies have attempted to identify the mechanisms underlying malignant tumor growth. Despite significant progress, most therapeutic approaches fail to eliminate all tumor cells. The remaining tumor cells often result in recurrence and metastasis. Recently, the idea of a cancer stem cell was prop...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.04.008

    authors: Zhao RC,Zhu YS,Shi Y

    更新日期:2008-07-01 00:00:00

  • Macrophage-derived angiogenesis factors.

    abstract::A majority of angiogenic factors has been shown to be produced by macrophages. This review will give a concise description of their biochemical nature, their isolation from macrophages and their angiogenic activity. Among the factors with mitogenic effects on endothelial cells are basic fibroblast growth factor (bFGF)...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90077-y

    authors: Sunderkötter C,Goebeler M,Schulze-Osthoff K,Bhardwaj R,Sorg C

    更新日期:1991-01-01 00:00:00

  • Molecular events in adipocyte development.

    abstract::Adipocyte hyperplasia occurs by the proliferation and differentiation of adipocyte precursor cells or preadipocytes. Although the process of commitment to the adipocyte lineage is poorly understood, a great deal of information has accumulated about the processes and regulatory mechanisms involved in preadipocyte diffe...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(94)90018-3

    authors: Butterwith SC

    更新日期:1994-01-01 00:00:00

  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.

    abstract::The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional C...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107587

    authors: Liu T,Luo S,Libby P,Shi GP

    更新日期:2020-09-01 00:00:00

  • Murine models for pharmacological studies of the metabolic syndrome.

    abstract::Metabolic syndrome has been described as the association of insulin resistance, hypertension, hyperlipidemia and obesity. Its prevalence increased dramatically, mainly in developed countries. Animal models are essential to understand the pathophysiology of this syndrome. This review presents the murine models of metab...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.11.004

    authors: Fellmann L,Nascimento AR,Tibiriça E,Bousquet P

    更新日期:2013-03-01 00:00:00

  • Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

    abstract::Dopamine D2 autoreceptors (D2ARs), located in somatodendritic and axon terminal compartments of dopamine (DA) neurons, function to provide a negative feedback regulatory control on DA neuron firing, DA synthesis, reuptake and release. Dysregulation of D2AR-mediated DA signaling is implicated in vulnerability to substa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107583

    authors: Chen R,Ferris MJ,Wang S

    更新日期:2020-09-01 00:00:00

  • Myotoxicity of statins: Mechanism of action.

    abstract::Statins are effective drugs to reduce cardiovascular events secondary to dyslipidemia; however, they cause frequent undesirable side effects. The incidence of statin-induced myotoxicity (SIM) is presented by 7 to 29% of patients, depending upon the report. SIM may develop in presence of abnormally high concentrations ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.02.029

    authors: du Souich P,Roederer G,Dufour R

    更新日期:2017-07-01 00:00:00

  • New drugs vs. old concepts: a fresh look at antiarrhythmics.

    abstract::Common arrhythmias, particularly atrial fibrillation (AF) and ventricular tachycardia/fibrillation (VT/VF) are a major public health concern. Classic antiarrhythmic (AA) drugs for AF are of limited effectiveness, and pose the risk of life-threatening VT/VF. For VT/VF, implantable cardiac defibrillators appear to be th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.03.003

    authors: Thireau J,Pasquié JL,Martel E,Le Guennec JY,Richard S

    更新日期:2011-11-01 00:00:00

  • Binge-eating disorder: Clinical and therapeutic advances.

    abstract::Binge-eating disorder (BED) is the most prevalent eating disorder with estimates of 2-5% of the general adult population. Nonetheless, its pathophysiology is poorly understood. Furthermore, there exist few therapeutic options for its effective treatment. Here we review the current state of binge-eating neurobiology an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.002

    authors: Hutson PH,Balodis IM,Potenza MN

    更新日期:2018-02-01 00:00:00

  • Cell imaging and morphology: application to studies of inherited purine metabolic disorders.

    abstract::A number of inherited or drug-induced metabolic disorders involving dysfunctions in purines and pyrimidines are strongly associated with neurological dysfunction, e.g., Lesch Nyhan syndrome. Such disorders have been studied extensively using biochemical and molecular techniques in order to examine how such defects occ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(01)00141-3

    authors: Connolly GP

    更新日期:2001-05-01 00:00:00

  • Role of pharmacotherapy in cardiac ion channelopathies.

    abstract::In the last decade, there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10%-15% of SCD occurs in the presence of structurall...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.09.002

    authors: El-Sherif N,Boutjdir M

    更新日期:2015-11-01 00:00:00

  • Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

    abstract::Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers. Incretins are defined as being responsible for the higher insulin release after an oral glucose load compared to an intravenous glucose load. ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.06.002

    authors: Verspohl EJ

    更新日期:2009-10-01 00:00:00

  • The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

    abstract::Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological e...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.02.005

    authors: Miller AM,Liew FY

    更新日期:2011-08-01 00:00:00

  • Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system.

    abstract::Cyclooxygenase (COX) enzymes, or prostaglandin-endoperoxide synthases (PTGS), are heme-containing bis-oxygenases that catalyze the first committed reaction in metabolism of arachidonic acid (AA) to the potent lipid mediators, prostanoids and thromboxanes. Two isozymes of COX enzymes (COX-1 and COX-2) have been identif...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.04.011

    authors: Hewett SJ,Bell SC,Hewett JA

    更新日期:2006-11-01 00:00:00

  • The structure and mechanism of bacterial type I signal peptidases. A novel antibiotic target.

    abstract::Type I signal peptidases are essential membrane-bound serine proteases that function to cleave the amino-terminal signal peptide extension from proteins that are translocated across biological membranes. The bacterial signal peptidases are unique serine proteases that utilize a Ser/Lys catalytic dyad mechanism in plac...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0163-7258(00)00064-4

    authors: Paetzel M,Dalbey RE,Strynadka NC

    更新日期:2000-07-01 00:00:00

  • Studies on anti-human immunodeficiency virus oligonucleotides that have alternating methylphosphonate/phosphodiester linkages.

    abstract::Preliminary investigations of the physical properties of oligonucleotide analogs that contain alternating methylphosphonate/phosphodiester linkages are described. An alternating oligo-2'-O-methylribonucleoside methylphosphonate, oligomer 1676, whose sequence is complementary to the upper hairpin region of human immuno...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(99)00054-6

    authors: Miller PS,Cassidy RA,Hamma T,Kondo NS

    更新日期:2000-03-01 00:00:00

  • Atypical behavioural effects of lorazepam: clues to the design of novel therapies?

    abstract::Aside from their pharmacokinetic properties, e.g. their speed of action and the duration of residual effects, benzodiazepines are still considered as equivalent in terms of their effects on cognition. Here we review evidence suggesting that certain benzodiazepines, especially lorazepam, differ in a number of respects,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.01.004

    authors: Giersch A,Boucart M,Elliott M,Vidailhet P

    更新日期:2010-04-01 00:00:00

  • Preventing asthma exacerbations: what are the targets?

    abstract::Exacerbations of asthma are the main cause of asthma morbidity. They induce acute respiratory failure, and sometimes death. Two immunological signals acting in synergy are necessary for inducing asthma exacerbations. The first, triggered by allergens and/or unknown agents leads to the chronic Th2 inflammation characte...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.03.010

    authors: Botturi K,Langelot M,Lair D,Pipet A,Pain M,Chesne J,Hassoun D,Lacoeuille Y,Cavaillès A,Magnan A

    更新日期:2011-07-01 00:00:00

  • Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

    abstract::Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost. Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders. Currently available drugs display limited efficacy and a pronounced delay to onset o...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.11.006

    authors: Millan MJ

    更新日期:2006-05-01 00:00:00

  • Leukotrienes and inflammation.

    abstract::The leukotrienes are synthesized from essential fatty acids via a 5-lipoxygenase enzyme. Most is known about the four-series leukotrienes derived from arachidonic acid. Leukotriene B4 is a potent chemotactic agent for leukocytes and it induces neutrophil-dependent increased microvascular permeability. Leukotrienes C4,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(90)90035-z

    authors: Brain SD,Williams TJ

    更新日期:1990-01-01 00:00:00

  • Matrix reloaded: CCN, tenascin and SIBLING group of matricellular proteins in orchestrating cancer hallmark capabilities.

    abstract::Matricellular proteins (MCPs) are the non-structural extracellular matrix (ECM) proteins with various regulatory functions. MCPs are critical regulators of ECM homeostasis and are often found dysregulated in various malignancies. They interact with various proteins like ECM structural proteins, integrins, growth facto...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.002

    authors: Thakur R,Mishra DP

    更新日期:2016-12-01 00:00:00

  • The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

    abstract::Methamphetamine (METH) abuse is a major public health issue around the world, yet there are currently no effective pharmacotherapies for the treatment of METH addiction. METH is a potent psychostimulant that increases extracellular dopamine levels by targeting the dopamine transporter (DAT) and alters neuronal activit...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.01.009

    authors: Sambo DO,Lebowitz JJ,Khoshbouei H

    更新日期:2018-06-01 00:00:00